BCDA — BioCardia, Inc.

Nasdaq · Health Care · Biotechnology · CIK 925741 ·
Last close
$0.95
Market Cap
$14.10M
52W High
$1.80
52W Low
$0.78
ADV30
5,726,369
Next earnings
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -2,266,000 -2,259,000 1,712,000 951,000 2,778,000
Dec 2025 0 -2,013,000 -1,984,000 3,413,000 2,496,000 2,518,000
Sep 2025 0 -1,488,000 -1,483,000 6,148,000 5,287,000 3,521,000
Jun 2025 0 -2,051,000 -2,049,000 2,089,000 980,000 3,975,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-7,477,000
Investing CF
$-10,000
Financing CF
$7,489,000
CapEx
$-12,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-1.44
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-170,608,000
Inventory
Receivables
$20,000
ST Investments
EBIT TTM
$-7,818,000
Pretax Income TTM
$-7,775,000
Interest Exp TTM
Analysts
2

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -8,278,000 -8,228,000 3,413,000 2,518,000 -7,436,000
Dec 2024 58,000 -8,001,000 -7,946,000 3,724,000 2,887,000 -7,886,000
Dec 2023 477,000 -11,644,000 -11,571,000 2,987,000 4,590,000 -9,974,000
Dec 2022 1,352,000 -11,901,000 -11,907,000 9,793,000 4,901,000 -10,561,000
Dec 2021

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.60

Peers — same industry

TickerNameMarket CapLastDaily %
INAB IN8BIO, INC. $14.10M $1.47
CKDXF Opthea Ltd $13.68M $0.01
ZEOX Zeo ScientifiX, Inc. $13.32M $1.70
JSPR Jasper Therapeutics, Inc. $13.20M $0.47
ZIVO Zivo Bioscience, Inc. $15.32M $3.69

News headlines (Yahoo Finance, 1h cache)

BioCardia Announces $4.4 Million Financing
2026-06-08 12:00 · Yahoo
Sector Update: Healthcare Stocks Higher Late Afternoon
2026-06-05 19:49 · Yahoo
Sector Update: Healthcare Stocks Gain Friday Afternoon
2026-06-05 17:50 · Yahoo
Top Midday Gainers
2026-06-05 17:29 · Yahoo
Why Did BCDA Stock Surge More Than 50% Today?
2026-06-05 16:25 · Yahoo
BioCardia Shares Rally After FDA Supports Regulatory Path for Heart Failure Therapy (BCDA)
2026-06-05 14:31 · Yahoo
FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF
2026-06-05 12:00 · Yahoo
BioCardia Announces Japan PMDA Record Of Advice Supports Regulatory Submission For Approval Of CardiAMP Cell Therapy For Ischemic Heart Failure
2026-05-28 12:00 · Yahoo
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency
2026-05-21 12:00 · Yahoo
BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
2026-05-19 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.